What is Helocyte?
Helocyte, Inc., a subsidiary of Fortress Biotech, Inc., is dedicated to the research and development of innovative immunotherapies. The company's primary focus lies in creating treatments to prevent and combat serious conditions such as cytomegalovirus (CMV), human immunodeficiency virus (HIV), and various forms of cancer. Helocyte targets healthcare providers and institutions that are at the forefront of oncology and infectious disease management, aiming to address critical unmet medical needs and improve patient outcomes through its advanced therapeutic candidates.
How much funding has Helocyte raised?
Helocyte has raised a total of $7M across 2 funding rounds:
Debt
$3M
Debt
$4M
Debt (2016): $3M, investors not publicly disclosed
Debt (2016): $4M, investors not publicly disclosed
What's next for Helocyte?
With the recent major strategic investment and substantial overall capital, Helocyte is poised for significant growth and advancement in its clinical development programs. The company's focus on immunotherapies for challenging diseases like CMV, HIV, and cancer indicates a strategic direction towards high-impact medical solutions. This enterprise-level backing suggests confidence in Helocyte's technology and its potential to address significant public health concerns. Future developments will likely involve progressing its pipeline through further clinical trials and potentially seeking strategic partnerships to broaden its market reach and therapeutic applications.
See full Helocyte company page
